Ipamorelin vs GHRP-6: GH Secretagogue Research Compared

Both ipamorelin and GHRP-6 are synthetic agonists of GHS-R1a, the growth hormone secretagogue receptor (the endogenous ghrelin receptor), expressed in the anterior pituitary, hypothalamus, and peripheral tissues. When GHS-R1a is activated in the pituitary, somatotrophs release GH. When activated in the hypothalamus, it also suppresses somatostatin — the endogenous GH-inhibiting peptide — amplifying the GH-releasing effect through a second pathway.

This shared receptor mechanism means both compounds produce measurable GH release at appropriate research concentrations. The published data confirms this. The differences arise in what else they activate.

GHRP-6 is a synthetic hexapeptide developed in the late 1970s as part of the original synthetic GH secretagogue programme. It is a potent GHS-R1a agonist — but an unselective one. At GH-effective doses, GHRP-6 activates receptor populations involved in pathways beyond the GH axis:

Cortisol co-stimulation — via HPA axis engagement through hypothalamic GHS-R1a. Published studies document cortisol elevations of 20–50% above baseline at doses that produce comparable GH release to ipamorelin.

ACTH co-stimulation — adrenocorticotropic hormone is released in parallel with GH, consistent with HPA involvement.

Appetite/hunger signalling — GHRP-6 activates ghrelin-sensitive circuits in the hypothalamus, producing a pronounced orexigenic (hunger-stimulating) effect well-documented in both animal models and human studies. This is a direct pharmacological consequence of GHS-R1a engagement in appetite-regulating neurons, not a secondary effect.

Prolactin co-stimulation — modest but measurable above baseline.

These are not side effects — they are direct, receptor-mediated actions. For research specifically examining GH-axis dynamics in isolation, they represent confounders. For research examining the full spectrum of GHS-R1a pharmacology — HPA responses, appetite regulation, orexigenic signalling — they are exactly the data point of interest.

Ipamorelin is a synthetic pentapeptide first published by Raun and colleagues in 1998. It was developed specifically to address the selectivity limitation of earlier GHRPs. The foundational 1998 paper demonstrated directly: ipamorelin at doses producing GH release equivalent to GHRP-6 produced no significant cortisol, prolactin, or ACTH co-stimulation above baseline.

This selectivity has been independently replicated and is the defining characteristic of ipamorelin in the published literature. The structural modifications in ipamorelin — relative to GHRP-6 — appear to bias the compound toward GH-somatotroph pathways while leaving HPA axis co-stimulation essentially absent at GH-effective doses.

The practical consequence: when using ipamorelin in a research protocol, GH release can be studied without the confounding variables introduced by concurrent cortisol elevation and appetite signalling.

GHRP-6 is the appropriate choice when the research is examining GHS-R1a pharmacology broadly — including HPA axis responses, orexigenic signalling, appetite regulation, or cortisol dynamics. The co-stimulation effects in GHRP-6 are data in these protocols, not noise.

Ipamorelin is the appropriate choice when GH-axis dynamics need to be studied without HPA confounders. Research examining GH pulsatility, downstream IGF-1 effects, somatostatin suppression, or growth hormone secretagogue pharmacokinetics where cortisol co-stimulation would complicate interpretation is better served by ipamorelin.

Combination with GHRH-class peptides: both compounds can be combined with GHRH-receptor agonists (CJC-1295 No DAC, Tesamorelin) for synergistic GH stimulation through complementary receptor pathways. The dual-receptor approach — GHS-R1a plus GHRHR simultaneously — produces GH pulses substantially greater than either class alone. See CJC-1295 No DAC and Ipamorelin: The Synergy in GH Research → for the mechanistic basis.

Both compounds are supplied as lyophilised powders requiring reconstitution with bacteriostatic water. Reconstituted solutions should be stored at 2–8°C and used within 28–30 days. See How to Reconstitute a Research Peptide → and Peptide Biological Half-Lives → for further protocol guidance.